In our patient (SCORTEN of 4), the decision for repeated etanercept dosing was based on persistently elevated inflammatory markers and hepatitis (Table I); of note, markers of end-organ damage continued to rise until the fourth dose, possibly related to a prolonged acute stage duration for which interleukin-6 has been positively correlated.5 This evidence concerns the gene IL6 and hepatitis A virus infection.